Viking Therapeutics with Positive Analyst Rating – Price Target at $93.60
This article was created with the help of artificial intelligence.
Key Takeaways
- Viking Therapeutics (VKTX) closed at $29.30 on August 28, 2026, a gain of 0.86% versus the prior day.
- 23 of 26 analysts assign a Buy or Strong Buy rating, with no analyst recommending a sale (as of August 28, 2026).
- The average analyst price target is $93.60, representing upside potential of approximately 219% from the current price.
- The company had liquid assets of $502 million at the end of the second quarter of 2026.
- The VENTURE study of VK2735 showed on January 12, 2026, weight loss of up to 14.7% after 13 weeks of treatment.
- The Relative Strength Index (RSI) stood at 48.13 points on August 27, 2026, in neutral territory.
Viking Therapeutics Inc. (NASDAQ: VKTX) traded at $29.30 on August 28, 2026, representing a gain of 0.86% compared to the previous day's close. The San Diego-based biopharmaceutical company, which specializes in developing therapies for metabolic and endocrine disorders, is moving within a range between the intraday low ($29.05) and intraday high ($29.60).
Analyst Consensus Shows Clear Upside Potential
Financial analysts' assessments are predominantly positive: Of 26 analyzed analyst opinions (as of August 28, 2026), nine analysts assign a "Strong Buy" rating, 14 a "Buy," and three a "Hold." Not a single analyst recommends selling the stock. The average price target stands at $93.60, while the median is at $95.00. The range of price targets extends from $83.00 (lowest target) to $101.00 (highest target).
Based on the average analyst price target of $93.60 compared to the current price, this implies a theoretical upside potential of approximately 219%. This discrepancy between market price and analyst estimates ranks among the higher values in the biotechnology sector.
Technical Indicators in Neutral Territory
The Relative Strength Index (RSI) stood at 48.13 points on August 27, 2026. The RSI is a technical indicator that measures the momentum of price movements and takes values between 0 and 100 – values below 30 are considered oversold, above 70 overbought. With a value just below 50, the VKTX stock is moving in neutral terrain, after the RSI fluctuated between 42.39 (August 13) and 50.54 points (August 26) over the past two weeks.
Strong Liquidity Position of the Company
Viking Therapeutics announced on July 29, 2026, that the company had liquid assets of $502 million at the end of the second quarter of 2026. This capital base provides the company with financial flexibility to continue its clinical development programs.
Clinical Pipeline with VK2735 Focus
The company's main focus is on VK2735, a dual GLP-1/GIP receptor agonist. A GLP-1/GIP receptor agonist is an active pharmaceutical ingredient that activates two hormone receptors involved in regulating blood sugar levels and body weight. On January 12, 2026, Viking released results from the VENTURE study of the subcutaneous form of VK2735. The Phase 2 data showed weight loss of up to 14.7% from baseline after 13 weeks of treatment, with no plateau observed.
In addition to the subcutaneous formulation, Viking is also developing an oral formulation of VK2735. Other product candidates in the pipeline include VK2809, an orally administered, tissue and receptor-selective thyroid hormone receptor beta (TRß) agonist, which is in Phase IIb studies for non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).
Market Environment for Obesity Therapeutics
Viking Therapeutics operates in a highly competitive market for obesity and diabetes medications. The sector has experienced high investor interest following the commercial success of established GLP-1 agonists such as semaglutide and tirzepatide. For smaller biotechnology companies like Viking, which have not yet commercialized approved products, the business model remains characterized by clinical development risks and financing challenges.
Trading volume for VKTX stock on August 28, 2026, was comparatively low at 5,244.70 shares traded, indicating a quiet trading environment on that day.